The Delaware Supreme Court last week upheld the dismissal of a 12-year-old class action accusing AstraZeneca of consumer fraud, saying the group of third-party payor health insurers could not claim injury under applicable state laws.
In Teamsters Local 237 Welfare Fund v. AstraZeneca Pharmaceuticals, the class of union health care funds alleged that AstraZeneca falsely advertised its prescription heartburn drug Nexium as superior to the less-expensive generic Prilosec, causing them to overpay for Nexium when the less-costly generic would have sufficed.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]